Posted by Michael Wonder on 22 Dec 2020
ViiV Healthcare announces the marketing authorisation of the first complete long-acting injectable HIV treatment in Europe
21 December 2020 - Marketing authorisation granted by European Commission for ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to be used with Janssen’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets).
ViiV Healthcare announced the authorisation of Vocabria (cabotegravir injection and tablets) in combination with Janssen's Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed.
